The trial conducted by Fondazione Salvatore Maugeri aims to evaluate the feasibility of a structured telesurveillance program combined with home cough assistance for ALS patients. Given the increasing prevalence of ALS and the need for innovative home care solutions, this program could represent a significant advancement in patient management, potentially reducing hospitalizations and improving quality of life. The market for ALS therapies and supportive care is growing, with increasing interest from both pharmaceutical companies and healthcare providers. The successful implementation of this program may enhance the competitive positioning of the sponsor in the ALS care landscape, particularly in telemedicine and home healthcare sectors. Diligence implications include assessing the scalability of the program and its cost-effectiveness compared to traditional care models.